Active Postmarketing Device Surveillance as a Legislative Priority

Passive safety surveillance of medical devices, relying on stakeholder reporting of problems, is fraught with limitations, whereas active safety surveillance, in which the FDA conducts routine post-marketing studies using real-world evidence, can provide a more complete picture of potential safety concerns. The authors make a case for better tracking of devices in medical claims and more funding for the FDA to conduct postmarketing surveillance studies.